Stay updated with breaking news from Therabionic Gmbh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Therabionic GmbH received U.S. FDA humanitarian device exemption (HDE) for its P1 device for at-home treatment of hepatocellular carcinoma, which accounts for 80% of all liver cancers, in patients who have failed first- and second-line therapies.
Study shows safety and efficacy of radio-wave therapy for liver cancer patients Researchers at Wake Forest School of Medicine have shown that a targeted therapy using non-thermal radio waves is safe to use in the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. The therapy also showed a benefit in overall survival. The study findings appear online in 4Open, a journal published by EDP Sciences. HCC accounts for nearly 90% of all liver cancers, and current survival rates are between six and 20 months. Currently, there are limited treatment options for patients ...